Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

<p>In our first insight, we covered the company's background, particularly its management team and its product pipeline.In this insight, we will discuss valuation and deal specific details. </p><h2>Thoughts on Valuation</h2><p>Given the limited drug candidates product pipeline and lack of income, we think the SOTP based on risk adjusted NPV valuation is a suitable valuation method for Zai Lab. Our valuation will encompass the following assumptions for each product:</p><ul><li>Annual case: We will take this number from the…</li></ul>

In our first insight, we covered the company's background, particularly its management team and its product pipeline.In this insight, we will discuss valuation and deal specific details. Thoughts on ValuationGiven the limited drug candidates product pipeline and lack of income, we think the SOTP based on risk adjusted NPV valuation is a suitable valuation method for Zai Lab. Our valuation will encompass the following assumptions for each product:Annual case: We will take this number from the…

Zai Lab IPO: Thoughts on Valuation, Risks and Upsides (Part 2)

<p>Zai Lab is looking to raise US$100m in the US listing. The company has a short history of three years and does not have a commercial product at the moment. In this insight, we will look at its history, team, product pipelines. In our follow up insight, we will look at its valuation. </p><h2>Company Background</h2><p>Zai Lab (再鼎医药) was founded in 2014 by experienced biopharmaceutical industrial practitioners. The company assembled a pipeline consisting of six drug candidates through partnerships with global…</p>

Zai Lab is looking to raise US$100m in the US listing. The company has a short history of three years and does not have a commercial product at the moment. In this insight, we will look at its history, team, product pipelines. In our follow up insight, we will look at its valuation. Company BackgroundZai Lab (再鼎医药) was founded in 2014 by experienced biopharmaceutical industrial practitioners. The company assembled a pipeline consisting of six drug candidates through partnerships with global…

Zai Lab IPO: Experienced Team, Promising In-Licensing Drug Pipeline (Part 1)

China

Zai Lab Limited operates as a bio-pharmaceutical company. The Company researches and develops therapeutic technology for antibody-based oncology, autoimmune, and infectious diseases treatments. Zai Lab also manufactures drugs in the form of capsules, injections, and liquids. Zai Lab serves patients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Zai Lab Ltd (ZLAB US)

Zai Lab IPO: Thoughts on Valuation, Risks and Upsides (Part 2)

In our first insight, we covered the company's background, particularly its management team and its product pipeline.In this insight, we will...

Ke Yan, CFA, FRM

Zai Lab IPO: Experienced Team, Promising In-Licensing Drug Pipeline (Part 1)

Zai Lab is looking to raise US$100m in the US listing. The company has a short history of three years and does not have a commercial product at the...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)